MDGL vs NVO
MDGL: Madrigal is a commercial-stage biotech company exclusively focused on Rezdiffra, the first FDA-approved treatment for MASH with moderate-to-advanced fibrosis, now scaling US and EU commercialization. NVO: A leading global healthcare company with a heritage in diabetes, pioneering scientific breakthroughs to defeat serious chronic diseases through innovative medicines and expanded access.
Side-by-side fundamentals
| Metric | MDGL | NVO | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $537.65 | $48.19 | |
| Market cap as of 2026-07-23 | $12.4B | $219.8B | |
| P/E as of 2026-07-23 | n/a | 11.78 | |
| PEG as of 2026-07-23 | n/a | 16.16 | |
| Net margin as of 2026-07-23 | -27.3% | +37.2% | NVO higher |
| Gross margin as of 2026-07-23 | +93.1% | +81.8% | MDGL higher |
| Operating margin as of 2026-07-23 | -27.9% | +45.3% | NVO higher |
| ROE as of 2026-07-23 | -50.1% | +66.4% | NVO higher |
| ROA as of 2026-07-23 | -25.4% | +23.3% | NVO higher |
| Debt / equity as of 2026-07-23 | 0.63 | 0.72 | MDGL lower |
| Revenue growth (YoY) as of 2026-07-23 | +256.8% | +8.1% | MDGL higher |
| Dividend yield as of 2026-07-23 | n/a | +3.7% | |
| Beta as of 2026-07-23 | -1.06 | 1.85 | |
| 1-year return as of 2026-07-22 close | +71.6% | -23.8% | MDGL higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.